Fusion Antibodies (LON:FAB) Stock Price Up 7.5% Following Insider Buying Activity

Shares of Fusion Antibodies plc (LON:FAB) rose 7.5% on Thursday following insider buying activity. The stock traded as high as GBX 3.19 ($0.04) and last traded at GBX 3.17 ($0.04). Approximately 218,985 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 1,029,427 shares. The stock had previously closed at GBX 2.95 ($0.04).

Specifically, insider Adrian Kinkaid acquired 120,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were bought at an average price of GBX 3 ($0.04) per share, for a total transaction of £3,600 ($4,733.73).

Fusion Antibodies Price Performance

The stock’s 50-day moving average price is GBX 3.21 and its 200 day moving average price is GBX 3.52. The firm has a market capitalization of £3.15 million, a price-to-earnings ratio of -82.50 and a beta of 0.48. The company has a quick ratio of 2.36, a current ratio of 3.26 and a debt-to-equity ratio of 3.23.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.